Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth FluMist Draft Label Will Be Reviewed By CDC Cmte. To Speed Coverage

Executive Summary

Wyeth has obtained permission from FDA to provide draft labeling for its intranasal flu vaccine FluMist to CDC's Advisory Committee on Immunization Practices in order to speed a coverage decision once the product is approved
Advertisement

Related Content

FluMist Pharmacy Administration In 36 States Upon Approval – MedImmune
FluMist Pharmacy Administration In 36 States Upon Approval – MedImmune
MedImmune FluMist “complete response”
FluMist Comparison To Inactivated Vaccine Suggested By FDA Committee
Aventis To Increase Fluzone Supply As Wyeth’s FluShield Exits Market
Advertisement
UsernamePublicRestriction

Register

PS041415

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel